Which works better, tirzepatide or semaglutide?

Head-to-head, tirzepatide averaged 20.2% loss versus semaglutide's 13.7% at 72 weeks — the efficacy verdict; molecule choice still weighs budget, comorbidity evidence, tolerability, and prescriber judgment.

Is tirzepatide worth the higher price?

At audited rates it's the better value: ~$83 per expected percentage point versus ~$96 for semaglutide.

When is semaglutide the right pick?

Hard budget caps, preference for its longer track record, or when its brand's cardiovascular/kidney evidence matters to your clinical picture.

Quick answer · /answers/ cluster · Molecule fork

Tirzepatide vs semaglutide — the quick verdict

QUICK ANSWER FILEUpdated August 17, 2026

THE SHORT ANSWER

Head-to-head in the only trial that ran them directly, tirzepatide averaged 20.2% body-weight loss versus semaglutide’s 13.7% at 72 weeks — a decisive efficacy win for the dual GIP/GLP-1 agonist, consistent with their separate pivotal trials (~20% SURMOUNT-class vs ~15% STEP-class). The quick decision frame: tirzepatide for maximum expected loss; semaglutide for budget floors, longer regulatory track, or when its specific label wins (cardiovascular-outcome and kidney evidence currently travel with semaglutide’s brand). Cost flips the intuition: at audited prices, tirzepatide’s $139 computes to ~$83 per expected point versus semaglutide’s ~$96 — the stronger molecule is also the better value. Clinical fit belongs to your prescriber; compounded versions of both are not FDA-approved.

The long versions: the head-to-head trial reread, why dual agonism adds effect, the comorbidity files where semaglutide’s certificates currently lead (cardiac, kidney), and the value math in full. Side-effect profiles run similar and GI-forward for both; tolerability, not preference, sometimes makes the choice.